Troke Admission medication ACE inhibitors A2 blockers Beta blockers Statins Presenting symptoms Chest pain Dyspnea Other ECG rhythm at CCU Sinus Atrial fibrillation ECG QRS at CCU Normal Pathological Q-wave Left bundle branch block Other ECG STT at CCU Normal ST-elevation ST-depression Other Pulmonary rales at CCU No Rales Other measures at CCU Troponin (ng) HR(bpm) SBP (mm Hg) Reperfusion at CCU No Primary PCI Discharge medication ACE inhibitors A2 blockers 31,547 (60.7) 6445 (12.4) 28,712 (62.1) 5670 (12.3) 2835 (49.6) 775 (13.6) < 0.0001 0.0046 34,469 (66.4) 14,665 (28.2) 29,740 (64.3) 13,884 (30.0) 4729 (82.8) 781 (13.7) < 0.0001 < 0.0001 1360 (310?460) 76 (65?0) 148.9 ?28.6 1350 (280?587) 75 (65?0) 143.0 ?28.2 1400 (319?0,000) 86 (71?6) 150.0 ?30.7 0.1761 < Naloxegol oxalate 0.0001 < 0.0001 46,205 (89.0) 3880 (7.5) 42,081 (91.0) 2762 (6.0) 4124 (72.2) 1118 (19.6) < 0.0001 < 0.0001 11,729 (22.6) 17,641 (34.0) 11,462 (22.1) 5820 (11.2) 10,805 (23.4) 16,251 (35.2) 9690 (21.0) 4726 (10.2) 924 (16.2) 1390 (24.3) 1772 (31.0) PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/1669444 1094 (19.2) < 0.0001 < 0.0001 < 0.0001 < 0.0001 35,819 (69.0) 5407 (10.4) 2458 (4.7) 5711 (11.0) 32,709 (70.7) 4753 (10.3) 1877 (4.1) 4862 (10.5) 3110 (54.5) 654 (11.5) 581 (10.2) 849 (14.9) < 0.0001 0.0062 < 0.0001 < 0.0001 46,297 (89.1) 4469 (8.6) 41,983 (90.8) 3308 (7.2) 4314 (75.6) 1161 (20.3) < 0.0001 < 0.0001 44,589 (85.8) 3472 (6.7) 3580 (6.9) 40,761 (88.2) 2368 (5.1) 2834 (6.1) 3828 (67.0) 1104 (19.3) 746 (13.1) < 0.0001 < 0.0001 < 0.0001 8409 (16.2) 5893 (11.3) 14,485 (27.9) 9904 (19.1) 7096 (15.3) 5164 (11.2) 12,084 (26.1) 8677 (18.8) 1313 (23.0) 729 (12.8) 2401 (42.0) 1227 (21.5) < 0.0001 0.0003 < 0.0001 < 0.0001 12,717 (24.5) 8552 (16.5) 23,432 (45.1) 3623 (7.0) 11,740 (25.4) 7046 (15.2) 20,386 (44.1) 2759 (6.0) 977 (17.1) 1506 (26.4) 3046 (53.3) 864 (15.1) < 0.0001 < 0.0001 < 0.0001 < 0.0001 All cases (n = 51,943) 68.8 ?12.3 33,620 (64.7) 79.1 ?15.9 31,654 (60.9) Survivors (n = 46,233) 67.5 ?11.9 30,523 (66.0) 72.1 ?15.6 27,816 (60.2) Non-survivors (n = 5710) 79.3 ?9.8 3097 (54.2) 80.0 ?16.3 3838 (67.2) Survivors vs. Non-survivors (P) < 0.0001 < 0.0001 < 0.0001 < 0.Wallert et al. BMC Medical Informatics and Decision Making (2017) 17:Page 6 ofTable 1 Predictors for all cases, by each class, and univariate class comparisons (Continued)Oral anticoagulants Other antiplatelet Beta blockers Statins ECG rhythm at discharge Atrial fibrillation 3703 (7.1) 2645 (5.7) 1058 (18.5) < 0.0001 2993 (5.8) 41,741 (80.4) 46,623 (89.8) 45,366 (87.3) PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/8309954 2514 (5.4) 38,461 (83.2) 41,789 (90.4) 41,918 (90.7) 479 (8.4) 3280 (57.4) 4834 (84.7) 3448 (60.4) < 0.0001 < 0.0001 < 0.0001 < 0.Values are mean ?SD or median (IQR) or count ( ). Uncorrected P-values are from Welch's t-tests if variable is Gaussian, Mann-Whitney U-tests if non-Gaussian, or Pearson's 2-tests if categorical ACE angiotensin-converting-enzyme, A2 angiotensin-2 receptor, CCU coronary care unit, ECG electrocardiogram, HR heart rate, PCI percutaneous coronary intervention, SBP systolic blood pressureperformance (0.822) significantly outperforming C5.0 (vs. 0.815, P = 0.0134), RF (vs. 0.795, P < 0.0001), and SVM (vs. 0.805, P < 0.0001). In addition, C5.0 performed significantly better than both RF (P < 0.0001) and SVM (P = 0.0014), and SVM performed significantly better than RF (P = 0.0195). See Table 2 for additional test results. Of the test set 2284 first MI patients found deceased 2 years later, the highest scoring model (SVM, 39 predictors) classified 1791 correctly and 493 incorre.